FibroGen (FGEN)
(Delayed Data from NSDQ)
$6.91 USD
-0.02 (-0.29%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $7.04 +0.13 (1.88%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FGEN 6.91 -0.02(-0.29%)
Will FGEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FGEN
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
Stevanato Group (STVN) Q1 Earnings and Revenues Top Estimates
FGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates
Other News for FGEN
Vanguard Group Inc Reduces Stake in FibroGen Inc
FibroGen to Report Second Quarter 2025 Financial Results | FGEN Stock News
Foresight Environmental Infrastructure Limited Adjusts Share Capital with Treasury Purchase
Director Makes Bold Move with Major FibroGen Stock Purchase
12 Health Care Stocks Moving In Wednesday's After-Market Session